🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

11 results for “Partner” Clear

  1. IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 75 mg film-coated tablets, IBRANCE 75 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules

    Partner Therapeutics Limited

    Female or male patients with histologically confirmed HR-positive, HER2-negative resected isolated locoregional recurrence (ILRR) of breast cancer.

    phase 3 small molecule active

    1 trial

  2. LIBTAYO 350 mg concentrate for solution for infusion.

    Partner Therapeutics Limited

    Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1%

    phase 3 small molecule active

    1 trial

  3. PEMETREXED , GEMCITABINE , PACLITAXEL , CISPLATIN , CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion.

    Partner Therapeutics Limited

    Stage IIB-IIIB (N2) resectable non small cell lung cancer

    phase 3 small molecule active

    1 trial

  4. Adagrasib

    Partner Therapeutics Limited

    Patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years with poor performance status (ECOG PS=2) Cohort 1 or elderly (≥70 years) (ECOG PS=0-1) Cohort 2

    phase 2 small molecule active

    1 trial

  5. IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion.

    Partner Therapeutics Limited

    NSCLC, synchronous oligo-metastatic

    phase 2 small molecule active

    1 trial

  6. IMFINZI 50 mg/mL concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion

    Partner Therapeutics Limited

    Extensive-disease small cell lung cancer and high SLFN11-expression

    phase 2 small molecule active

    1 trial

  7. JNJ-73841937, JNJ-61186372, Zirabev 25 mg/ml concentrate for solution for infusion.

    Partner Therapeutics Limited

    Patients with EGFR-mutant (L858R or del19 only) advanced non-squamous NSCLC, who have progressed on previous treatment with a third-generation EGFR-TKI.

    phase 2 small molecule active

    1 trial

  8. MCLA-128

    Partner Therapeutics Limited

    Solid Tumors

    phase 2 small molecule active

    1 trial

  9. Pamorelin® LA 3,75 mg Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension, RO7197597, ANASTROZOLE ACCORD 1 mg, comprimé pelliculé

    Partner Therapeutics Limited

    ER-positive/HER2-negative early breast cancer

    phase 2 small molecule active

    1 trial

  10. Tarlatamab, Tarlatamab

    Partner Therapeutics Limited

    Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2

    phase 2 small molecule active

    1 trial

  11. Multi-media WINGS

    BRIGHT MINDS BIOSCIENCES INC.

    Intimate Partner Violence

    phase 1 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources